Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Agios Pharmaceuticals (AGIO) Interest & Investment Income (2016 - 2025)

Historic Interest & Investment Income for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to $13.4 million.

  • Agios Pharmaceuticals' Interest & Investment Income rose 237.38% to $13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.0 million, marking a year-over-year increase of 6019.85%. This contributed to the annual value of $48.1 million for FY2024, which is 4420.29% up from last year.
  • Agios Pharmaceuticals' Interest & Investment Income amounted to $13.4 million in Q3 2025, which was up 237.38% from $14.5 million recorded in Q2 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Interest & Investment Income peaked at $18.0 million during Q4 2024, and registered a low of -$92000.0 during Q2 2021.
  • Moreover, its 5-year median value for Interest & Investment Income was $8.1 million (2024), whereas its average is $7.3 million.
  • In the last 5 years, Agios Pharmaceuticals' Interest & Investment Income plummeted by 10520.07% in 2021 and then surged by 204891.3% in 2022.
  • Over the past 5 years, Agios Pharmaceuticals' Interest & Investment Income (Quarter) stood at $332000.0 in 2021, then skyrocketed by 1854.22% to $6.5 million in 2022, then soared by 32.92% to $8.6 million in 2023, then soared by 108.89% to $18.0 million in 2024, then dropped by 25.79% to $13.4 million in 2025.
  • Its last three reported values are $13.4 million in Q3 2025, $14.5 million for Q2 2025, and $16.1 million during Q1 2025.